Maximus/$MMS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Maximus
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
- Ticker
- $MMS
- Sector
- Business services
- Primary listing
- NYSE
- Employees
- 37,200
- Headquarters
- McLean, United States
- Website
- www.maximus.com
Maximus Metrics
BasicAdvanced
$3.3B
9.46
$6.74
0.58
$1.29
2.07%
Price and volume
Market cap
$3.3B
Beta
0.58
52-week high
$100.00
52-week low
$51.04
Average daily volume
674K
Dividend rate
$1.29
Financial strength
Current ratio
2.421
Quick ratio
2.168
Long term debt to equity
0.932
Total debt to equity
0.995
Dividend payout ratio (TTM)
18.41%
Interest coverage (TTM)
6.49%
Profitability
EBITDA (TTM)
691.836
Gross margin (TTM)
25.59%
Net profit margin (TTM)
7.07%
Operating margin (TTM)
11.03%
Effective tax rate (TTM)
24.53%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
8.20%
Return on equity (TTM)
21.11%
Valuation
Price to earnings (TTM)
9.458
Price to revenue (TTM)
0.662
Price to book
1.92
Price to tangible book (TTM)
-4.64
Price to free cash flow (TTM)
8.025
Free cash flow yield (TTM)
12.46%
Free cash flow per share (TTM)
7.94
Dividend yield (TTM)
2.02%
Forward dividend yield
2.07%
Growth
Revenue change (TTM)
-3.32%
Earnings per share change (TTM)
25.45%
3-year revenue growth (CAGR)
2.87%
10-year revenue growth (CAGR)
8.33%
3-year earnings per share growth (CAGR)
34.10%
10-year earnings per share growth (CAGR)
10.66%
3-year dividend per share growth (CAGR)
4.00%
10-year dividend per share growth (CAGR)
21.48%
What the Analysts think about Maximus
Analyst ratings (Buy, Hold, Sell) for Maximus stock.
Analyst projections of the future price of Maximus stock.
Bulls say / Bears say
Adjusted EPS rose to $2.22 from $2.16 year on year, while adjusted EBITDA margin improved to 15.0% from 14.7%, despite lower revenue. Maximus credited efficiency initiatives, including automation and AI-enabled tools, for helping lift earnings. (Maximus, Inc.)
Maximus expects its U.S. Services segment to return to positive organic growth, with higher Medicaid outreach and engagement activity driving volumes. Management expects that growth to continue into fiscal 2027. (Maximus, Inc.)
Awarded-but-unsigned contracts rose to $1.35 billion from $322 million the previous quarter, mainly through successful longer-term contract recompetes. If signed and mobilised, these wins could support future revenue. (Maximus, Inc.)
A customer pause in performance incentives on the VA medical exam programme cut Maximus’s FY2026 adjusted EPS guidance by about $0.35 per share. The company expects the pause to continue through December, also affecting the first quarter of FY2027. (Maximus, Inc., Maximus, Inc.)
Federal contract conversion is weak: trailing 12-month book-to-bill was about 0.5x, while some civilian opportunities faced delays, scope changes or cancellation. A large pipeline therefore may not translate into awards or revenue quickly. (Maximus, Inc.)
The Outside the U.S. segment remains a drag, with quarterly revenue down to $140 million from $147 million and operating margin falling to 0.9% from 4.0%. Management still expects the segment only to break even for the full year. (Maximus, Inc.)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Maximus Financial Performance
Revenues and expenses
Maximus Earnings Performance
Company profitability
Upcoming events
Maximus News
AllArticlesVideos
Funds containing Maximus
AllUSDEURGBP
Fund name | Fund size | $MMS weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.31% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.31% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.31% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.